{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:56:14Z","timestamp":1753440974947},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The safety and efficacy of CRS\u2009+\u2009HIPEC combined with urinary tract resection and reconstruction are controversial. This study aims to summarize the clinicopathological features and to evaluate the safety and survival prognosis of CRS\u2009+\u2009HIPEC combined with urinary tract resection and reconstruction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The patients who underwent urinary tract resection and reconstruction as part of CRS surgery were retrospectively selected from our disease-specific database for analysis. The clinicopathological characteristics, treatment-related variables, perioperative adverse events (AEs), and survival outcomes were studied using a descriptive approach and the K-M analysis with log-rank comparison.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty-nine patients were enrolled. Perioperative serious AEs (SAEs) were observed in 11 patients (22.4%), with urinary SAEs occurring in 3 patients (6.1%). Additionally, there were 23 cases (46.8%) involving urinary adverse events (UAEs). The median overall survival (OS) in the entire cohort was 59.2 (95%CI: 42.1\u201376.4) months. The median OS of the UAE group and No-UAE group were 59.2 months (95%CI not reached), and 50.5 (95%CI: 11.5 to 89.6) months, respectively, with no significant difference (<jats:italic>P<\/jats:italic>\u2009=\u20090.475). Furthermore, there were no significant differences in OS based on the grade of UAEs or the number of UAEs (<jats:italic>P<\/jats:italic>\u2009=\u20090.562 and <jats:italic>P<\/jats:italic>\u2009=\u20090.622, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The combination of CRS\u2009+\u2009HIPEC with urinary tract resection and reconstruction is associated with a high incidence of Grade I-II UAEs, which do not have an impact on OS. The safety profile of this combined technique is acceptable. However, this is a retrospective single-center single-arm analysis, with limitations of generalizability and potential selection bias. The findings need high-level validation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-024-03457-8","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T10:06:57Z","timestamp":1719396417000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intraoperative urinary tract resection and construction in CRS\u2009+\u2009HIPEC procedures: a single center retrospective analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Zhong-He","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Bin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Dong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"1","key":"3457_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36\u201359.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"3457_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","volume":"47","author":"K Govaerts","year":"2021","unstructured":"Govaerts K, Lurvink RJ, De Hingh I, et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47(1):11\u201335.","journal-title":"Eur J Surg Oncol"},{"issue":"30","key":"3457_CR3","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.3748\/wjg.v22.i30.6906","volume":"22","author":"Y Li","year":"2016","unstructured":"Li Y, Zhou YF, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol. 2016;22(30):6906\u201316.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3457_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cortes-Guiral","year":"2021","unstructured":"Cortes-Guiral D, Hubner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91.","journal-title":"Nat Rev Dis Primers"},{"issue":"03","key":"3457_CR5","first-page":"230","volume":"24","author":"Y Yu","year":"2021","unstructured":"Yu Y, Li XB, Lin YL, et al. Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Chin J Gastroenterol Surg. 2021;24(03):230\u20139.","journal-title":"Chin J Gastroenterol Surg"},{"issue":"1","key":"3457_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29\u201342.","journal-title":"Ann Surg"},{"key":"3457_CR7","doi-asserted-by":"crossref","unstructured":"Tuech JJ, Pinson J, Nouhaud FX et al. Total pelvic exenteration, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy for rectal cancer with associate peritoneal metastases: surgical strategies to optimize safety. Cancers (Basel) 2020; 12(11).","DOI":"10.3390\/cancers12113478"},{"key":"3457_CR8","unstructured":"Sugarbaker PH, Speeten KVD, Stuart OA, et al. In: Sugarbaker PH, editor. Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. Cytoreductice surgery & perioperative chemotherapy for peritoneal surface malignancy. Woodbury; Cine-Med Inc; 2017."},{"issue":"2","key":"3457_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol"},{"issue":"9","key":"3457_CR10","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"3457_CR11","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"3457_CR12","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028\u201340.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3457_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"36","key":"3457_CR14","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342.","journal-title":"J Clin Oncol"},{"issue":"20","key":"3457_CR15","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449\u201356.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3457_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jviscsurg.2015.01.004","volume":"152","author":"JJ Tuech","year":"2015","unstructured":"Tuech JJ, Schwarz L, Coget J, et al. Difficult hemostasis during radical pelvic surgery. J Visc Surg. 2015;152(2):119\u201324.","journal-title":"J Visc Surg"},{"issue":"1","key":"3457_CR17","first-page":"295","volume":"35","author":"HJ Braam","year":"2015","unstructured":"Braam HJ, Van Oudheusden TR, De Hingh IH, et al. Urological procedures in patients with peritoneal carcinomatosis of colorectal cancer treated with HIPEC: morbidity and survival analysis. Anticancer Res. 2015;35(1):295\u2013300.","journal-title":"Anticancer Res"},{"key":"3457_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.suronc.2020.12.001","volume":"36","author":"PA Cascales-Campos","year":"2021","unstructured":"Cascales-Campos PA, Gonz\u00e1lez-Gil A, Fern\u00e1ndez-Luna E, et al. Urinary and fecal incontinence in patients with advanced ovarian cancer treated with CRS\u2009+\u2009HIPEC. Surg Oncol. 2021;36:115\u20139.","journal-title":"Surg Oncol"},{"issue":"1","key":"3457_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12957-019-1770-x","volume":"17","author":"\u015eB Morkavuk","year":"2019","unstructured":"Morkavuk \u015eB, G\u00fcner M, Tez M, et al. The outcomes of isolated ureteral resection and reconstruction in non-urologic cancer patients who underwent cytoreductive surgery (CRC) and hyperthermic intraperitoneal chemotherapy (HIPEC). World J Surg Oncol. 2019;17(1):230.","journal-title":"World J Surg Oncol"},{"issue":"24","key":"3457_CR20","first-page":"1273","volume":"49","author":"OC Pedro Barrios","year":"2022","unstructured":"Pedro Barrios OC, Montse Mart\u00edn I, Ramos. Radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy plus total pelvic exenteration in patient with peritoneal metastasis and advanced pelvic disease. Chin J Clin Oncol. 2022;49(24):1273\u20136.","journal-title":"Chin J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03457-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T10:07:19Z","timestamp":1719396439000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03457-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3457"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03457-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board and the ethics committee of Beijing Shijitan Hospital affiliated to Capital Medical University (2015-28). All patients signed preoperative Institutional Review Board-approved consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}